摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-azido-2,4-difluorobenzene | 91229-55-9

中文名称
——
中文别名
——
英文名称
1-azido-2,4-difluorobenzene
英文别名
2,4-difluorophenyl azide
1-azido-2,4-difluorobenzene化学式
CAS
91229-55-9
化学式
C6H3F2N3
mdl
MFCD00211388
分子量
155.107
InChiKey
YMCOFIHJJULAOJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    14.4
  • 氢给体数:
    0
  • 氢受体数:
    4

SDS

SDS:540d8859eab9c5b5227d17d0098c527d
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-azido-2,4-difluorobenzenecopper(l) iodideN,N-二异丙基乙胺 作用下, 以 1,4-二氧六环乙腈 为溶剂, 反应 74.0h, 生成 4-(5-fluoro-2-(4-phenyl-1H-1,2,3-triazol-1-yl)phenyl)morpholine
    参考文献:
    名称:
    三唑基和相关杂芳基取代基对 SNAr 反应的加速作用:氢键稳定过渡态的证据
    摘要:
    通过系统实验和密度泛函理论计算研究了 1,2,3-三唑基取代基对 SNAr 反应的显着加速作用。邻三唑基取代基的孤对电子通过与处于加成过渡态的胺亲核试剂形成优先氢键,在降低亲核加成的活化能方面发挥关键作用。在这一发现的扩展中,还发现了一系列具有相似电子对供体特性的相关杂芳基促进 SNAr 反应。实验确定的溶剂效应为这一原理提供了进一步的支持,该原理用于在二氟芳烃底物上实现邻位选择性取代。
    DOI:
    10.1021/jacs.5b06189
  • 作为产物:
    描述:
    2,4-二氟硝基苯 在 sodium azide 作用下, 以 1,4-二氧六环 为溶剂, 生成 1-azido-2,4-difluorobenzene
    参考文献:
    名称:
    Click chemistry inspired facile synthesis and bioevaluation of novel triazolyl analogs of Ludartin
    摘要:
    A convenient and modular synthesis involving diastereoselective Michael addition followed by regioselective Huisgen 1,3-dipolar cycloaddition reaction was carried out to furnish 1,4-disubstituted-1,2,3-triazoles of Ludartin. This reaction scheme involving Michael addition followed by regioselective Huisgen 1,3-dipolar cycloaddition reaction leading to the formation of triazolyl analogs is being reported for the first time. All the triazolyl products were characterised using spectral data analysis. Sulphorhodamine B cytotoxicity screening of the resulting products against a panel of five human cancerous cell-lines revealed that few of the analogs display promising broad spectrum cytotoxic effect. Among all the synthesized compounds, only 3q displayed the best cytotoxic effect with IC50 values of 12, 11, 38, 39 and 8.5 mu M but less than the standard Ludartin (1) with IC50 values of 6.3, 7.4, 7.5, 6.9 and 0.5 mu M against human neuroblastoma (T98G), lung (A-549), prostate (PC-3), colon (HCT-116) and breast (MCF-7) cancer cell lines, respectively. The present synthesis was designed based on the previous literature reports of Ludartin as an aromatase inhibitor. Our work provides an initial study on structure-activity relationship of triazolyl analogs of sesquiterpene lactones in general and Ludartin (1) in particular. (C) 2014 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2014.01.018
点击查看最新优质反应信息

文献信息

  • Synthesis of newer 1,2,3-triazole linked chalcone and flavone hybrid compounds and evaluation of their antimicrobial and cytotoxic activities
    作者:Rama Kant、Dharmendra Kumar、Drishti Agarwal、Rinkoo Devi Gupta、Ragini Tilak、Satish Kumar Awasthi、Alka Agarwal
    DOI:10.1016/j.ejmech.2016.02.041
    日期:2016.5
    The antiplasmodial and cytotoxic activities of these compounds were also evaluated against human malaria parasite Plasmodium falciparum strain 3D7 and human hepato-cellular carcinoma cells (Huh-7), respectively. Compounds 10a, 10c, 10d, 12c and 14e showed promising antibacterial activity while compounds 10e, 11d, 11e, 12c, 13a, 13b, 13e, 14a and 14d showed good antifungal activity as compared to the corresponding
    本研究旨在通过铜催化点击化学合成一类新的抗菌剂和抗疟原虫剂,以提供25种1,4-二取代-1,2,3-三唑的化合物10–14(a – e)。查耳酮和黄酮的衍生物。通过元素分析,IR,1 H NMR,13 C NMR和质谱数据建立了新合成化合物的结构。评价了新合成的化合物对革兰氏阳性细菌(金黄色葡萄球菌,粪肠球菌),革兰氏阴性细菌(大肠杆菌,铜绿假单胞菌,志贺氏菌鲍氏,肺炎克雷伯菌)和抗真菌活性(白色念珠菌,热带念珠菌,近平滑念珠菌,新型隐球菌,皮肤癣菌)以及模具(黑曲霉,烟曲霉)。还分别评估了这些化合物对人疟原虫恶性疟原虫菌株3D7和人肝细胞癌细胞(Huh-7)的抗血浆和细胞毒活性。化合物10a,10c,10d,12c和14e与相应的标准药物相比,化合物10e,11d,11e,12c,13a,13b,13e,14a和14d表现出良好的抗菌活性。发现化合物10b对恶性疟原虫最具活性,而其余化合
  • Synthesis of 5-hydroxy- and 5-sulfanyl-substituted [1,2,3]triazolo[4,5-е][1,4]diazepines
    作者:Sergiy V. Kemskiy、Natalia A. Syrota、Andriy V. Bol’but、Viktor I. Dorokhov、Mykhaylo V. Vovk
    DOI:10.1007/s10593-018-2350-7
    日期:2018.8
    5-Amino-N-(2,2-dimethoxyethyl)-1Н-1,2,3-triazole-4-carboxamides in formic acid were subjected to intramolecular cyclization to 5-hydroxy[1,2,3]triazolo[4,5-е][1,4]diazepines, which were converted by treatment with S-nucleophiles to 5-thio-functionalized derivatives.
    5-氨基- ñ - (2,2-二甲氧基乙基)-1- Н 1,2,3-三唑-4-甲酰胺在甲酸进行分子内环化以5-羟基- [1,2,3]三唑并[4 ,5- е ] [1,4]二氮杂,,通过用S-亲核试剂处理将其转化为5-硫代官能化衍生物。
  • BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS
    申请人:CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC.
    公开号:US20180170938A1
    公开(公告)日:2018-06-21
    The present invention relates to 1,3-disubstituted-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives, 5,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives or 5,7-disubstituted-imidazo[5,1-f][1,2,4]triazine-4-amine derivatives, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compounds, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjôgren's Syndrome, and other CFTR associated disorders.
    本发明涉及1,3-二取代-1H-吡唑并[3,4-d]嘧啶-4-胺衍生物,5,7-二取代-吡咯并[2,1-f][1,2,4]三嗪-4-胺衍生物或5,7-二取代-咪唑并[5,1-f][1,2,4]三嗪-4-胺衍生物,以及其药学上可接受的盐。这些化合物是囊性纤维化跨膜传导调节蛋白(CFTR)的增效剂。该发明还揭示了包括这些化合物的药物组合物,可选地与额外的治疗剂联合使用,以及通过给予这些化合物来增强哺乳动物,包括人类,CFTR的方法。这些化合物对于囊性纤维化(CF)、哮喘、支气管扩张、慢性阻塞性肺病(COPD)、便秘、糖尿病、干眼病、胰腺炎、鼻窦炎、Sjôgren综合征和其他CFTR相关疾病的治疗是有用的。
  • Synthesis of novel 1-substituted triazole linked 1,2-benzothiazine 1,1-dioxido propenone derivatives as potent anti-inflammatory agents and inhibitors of monocyte-to-macrophage differentiation
    作者:Malla Reddy Gannarapu、Sathish Babu Vasamsetti、Nagender Punna、Srigiridhar Kotamraju、Narsaiah Banda
    DOI:10.1039/c5md00171d
    日期:——

    Compounds12g,12iand12lmodulate pro-inflammatory cytokine production by inhibiting monocyte differentiation.

    化合物12g,12i和12l通过抑制单核细胞分化来调节促炎细胞因子的产生。
  • Synthesis and biological evaluation of triazole based uracil derivatives as novel DPP-4 inhibitors
    作者:Qing Li、Li Han、Bin Zhang、Jinpei Zhou、Huibin Zhang
    DOI:10.1039/c6ob01818a
    日期:——
    A series of triazole based uracil derivatives were designed and synthesized as novel DPP-4 inhibitors. Compound A01 was identified as a lead compound for SAR studies focused on the structural modification at the S2′ subsite of DPP-4. The novel analogues A02–A25 were obtained by modifying the substituents at the phenyl group, and B01–B09, by introducing the carbonyl group. On screening in DPP-4, compounds
    设计并合成了一系列基于三唑的尿嘧啶衍生物,作为新型DPP-4抑制剂。化合物A01被确定为SAR研究的先导化合物,专注于DPP-4的S 2'亚位点的结构修饰。通过修饰苯基和B01-B09的取代基(通过引入羰基)获得了新的类似物A02-A25。在DPP-4中进行筛选时,与化合物A01相比,化合物B03,B04和B08的DPP-4抑制活性显着提高并显示出与市售DPP-4抑制剂阿格列汀相当的活性。对接研究在S揭示设计的化合物的新的有利的结合模式2'亚位点,并证明了在S结构修饰2'亚位点是增加DPP-4抑制的有效的选择。体外DPP-8和DPP-9测试表明,所有化合物均对DPP-8和DPP-9表现出优异的选择性。进一步的体内评估表明,化合物B04可以显着改善ICR小鼠的口服葡萄糖耐量,并剂量依赖性地降低2型糖尿病C57BL / 6小鼠的葡萄糖水平。这些数据表明化合物B04 可能是将来治疗T2DM的有希望的DPP-4抑制剂。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐